A new study identifies potential immune profile differences in patients with chronic lymphocytic leukemia (CLL) that may lead to resistance after ibrutinib therapy. Researchers analyzed peripheral ...

Medical experts provide an overview of chronic lymphocytic leukemia (CLL), including its typical symptoms and diagnostic process. They also will inquire about key prognostic factors and their impact ...

Covalent BTK inhibitors and Bcl-2 inhibitors are primary treatments for CLL, but alternatives are needed for relapsed or refractory cases. Treatment sequencing is vital, with potential switches ...

Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer Chronic lymphocytic leukemia (CLL) has unique epidemiologic, biologic, and clinical ...

Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL). As treatment ...

Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...